Compare Neurocrine Biosciences Inc (NBIX) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Clear Secure Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Clear Secure Inc trades at $43.42 (market cap $4.49B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.5× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.32% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | YOU | |
|---|---|---|
Market Cap | $15.77B | $4.49B |
Sector | Health | Technology |
52-Week High | $185.50 | $62.36 |
52-Week Low | $123.10 | $29.61 |
Enterprise Value | $15.78B | $3.64B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Clear Secure (YOU) trades at $43.6, down 1.65% on the day, amid a bearish technical signal. The company shows strong fundamental momentum with 27% year-over-year revenue growth in Q2 2026 and expanding profitability, though valuation ratios like a P/E of 29.46 appear elevated. Recent news highlights a strategic partnership with CrowdStrike and the launch of corporate memberships, signaling growth initiatives beyond airports.
The outlook is mixed: robust earnings beats and membership growth support upside, but high valuation and insider selling pose risks. Analyst consensus is evenly split between Buy and Hold, reflecting cautious optimism. Key near-term catalysts include Q3 2026 earnings and the success of new enterprise offerings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
